Antibody-Drug Conjugate that Exhibits Synergistic Cytotoxicity with an Endosome-Disruptive Peptide

Area of Science:

• Oncology
• Molecular Biology
• Drug Delivery

Background:

• Antibody-drug conjugates (ADCs) are key cancer therapeutics that rely on intracellular toxin release.
• Conventional ADCs often use membrane-permeable toxins, limiting their efficacy and increasing systemic toxicity.
• The endosomal-lysosomal system is crucial for ADC processing and subsequent cytotoxin release.

Purpose of the Study:

• To develop a novel ADC strategy utilizing a membrane-impermeable cytotoxin.
• To investigate the synergistic effect of an endosome-disruptive peptide on ADC-mediated cytotoxicity.
• To enhance the targeted delivery and efficacy of cancer therapeutics.

Main Methods:

• Conjugation of an anionic colchinol methyl ether derivative to trastuzumab (Herceptin) via a disulfide bond.
• Utilizing HER2-positive SKBR3 breast cancer cells for in vitro validation.
• Co-administration of the ADC with a cholesterol-linked, non-toxic endosome-disruptive peptide.

Main Results:

• The antibody-drug conjugate alone exhibited low cytotoxicity (IC50 > 1 μM) due to endosomal trapping of the membrane-impermeable toxin.
• Co-administration with the endosome-disruptive peptide significantly enhanced cytotoxicity, achieving subnanomolar potency (IC50 = 0.11 ± 0.07 nM).
• The peptide facilitated endosomal escape of the cytotoxin without significantly affecting disulfide bond cleavage or promoting glutathione influx.

Conclusions:

• A novel antibody-drug conjugate approach using a membrane-impermeable cytotoxin and an endosome-disruptive peptide offers potent and targeted cancer therapy.
• This strategy overcomes limitations of conventional ADCs by enabling efficient cytoplasmic delivery of the payload.
• The findings suggest a promising new direction for developing next-generation antibody-drug conjugates with improved efficacy and safety profiles.